BMS leases biologic development space in New Jersey to PTC

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Bms, Biologics, development, New jersey

Bristol-Myers Squibb and PTC Therapeutics enter a long-term lease agreement giving the latter greater access to biologic production facility as it advances its treatments for rare genetic disorders.

PTC Therapeutics signed a long-term lease agreement with Bristol-Myers Squibb (BMS) to gain access to a 185,000 square foot space in Hopewell, NJ. The site, located on BMS’ property, includes a biologics production facility, and research and operations buildings.

With this 15-year lease agreement, PTC plans to further develop the biologics facility in an aim to support its gene therapy production capabilities. The site’s current good manufacturing practice (cGMP) suites will be used to produce material to serve PTC’s pre-clinical and clinical programs.

The company focuses on developing treatments for rare genetic disorders, specifically, therapies for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA).

Additionally, PTC intends to move its research operations to the site complementing existing operations at the company’s existing New Jersey productions. A spokesperson for the company told us that PTC has been in New Jersey for over 21 years.

PTC also stated that it has plans to relocate and expand its discovery and research operations to the site in 2020.

Related topics: Downstream Processing, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more